Amphastar Pharmaceuticals (NASDAQ:AMPH) EVP Sells $75,308.81 in Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) EVP Rong Zhou sold 3,187 shares of the company’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $23.63, for a total transaction of $75,308.81. Following the completion of the transaction, the executive vice president owned 169,203 shares in the company, valued at $3,998,266.89. This represents a 1.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Amphastar Pharmaceuticals Trading Down 2.8%

AMPH opened at $23.18 on Friday. Amphastar Pharmaceuticals, Inc. has a 52 week low of $16.65 and a 52 week high of $29.78. The company has a quick ratio of 1.71, a current ratio of 2.40 and a debt-to-equity ratio of 0.79. The stock’s fifty day moving average is $20.51 and its two-hundred day moving average is $20.61. The company has a market capitalization of $986.08 million, a P/E ratio of 13.72, a PEG ratio of 4.47 and a beta of 0.92.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.62 by $0.29. The company had revenue of $183.90 million for the quarter, compared to analyst estimates of $179.92 million. Amphastar Pharmaceuticals had a net margin of 10.76% and a return on equity of 14.98%. Analysts forecast that Amphastar Pharmaceuticals, Inc. will post 2.46 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on AMPH. Zacks Research raised Amphastar Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 21st. Barclays upped their target price on Amphastar Pharmaceuticals from $20.00 to $23.00 and gave the company an “equal weight” rating in a research report on Tuesday, August 18th. Piper Sandler lowered their price target on Amphastar Pharmaceuticals from $21.00 to $20.00 and set a “neutral” rating for the company in a report on Friday, August 7th. Weiss Ratings restated a “sell (d+)” rating on shares of Amphastar Pharmaceuticals in a research note on Wednesday, July 8th. Finally, Wells Fargo & Company upped their price objective on shares of Amphastar Pharmaceuticals from $19.00 to $20.00 and gave the company an “equal weight” rating in a report on Friday, August 7th. Six equities research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Reduce” and an average target price of $22.50.

Institutional Trading of Amphastar Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Quarry LP acquired a new position in shares of Amphastar Pharmaceuticals in the third quarter valued at about $32,000. Farther Finance Advisors LLC raised its stake in shares of Amphastar Pharmaceuticals by 46.3% in the fourth quarter. Farther Finance Advisors LLC now owns 1,381 shares of the company’s stock worth $37,000 after purchasing an additional 437 shares during the last quarter. Quantbot Technologies LP acquired a new stake in shares of Amphastar Pharmaceuticals during the second quarter worth about $39,000. TD Private Client Wealth LLC lifted its holdings in shares of Amphastar Pharmaceuticals by 410.1% during the fourth quarter. TD Private Client Wealth LLC now owns 2,418 shares of the company’s stock worth $65,000 after purchasing an additional 1,944 shares during the period. Finally, Quadrant Capital Group LLC purchased a new stake in Amphastar Pharmaceuticals in the third quarter valued at approximately $82,000. Institutional investors and hedge funds own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.